Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus

NCT01683266 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

549

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: HOE901-U300 (Insulin glargine new formulation)
DRUG: Lantus (Insulin glargine)

Sponsor

Sanofi